| A1 and A2A | Adenosine receptors |
| AD | Alzheimer’s disease |
| BPND | Binding potential |
| Bq | Becquerel |
| CAG | Cytosine-adenine-guanine |
| CB1 | Cannabinoid receptor type 1 |
| CNS | Central nervous system |
| D1, D2 and D3 | Dopamine receptors |
| DMF | Dimethyl formamide |
| DMSO | Dimethyl sulfoxide |
| GABA | gamma-Aminobutyric acid |
| GMP | Good manufacturing practice |
| HD | Huntington’s disease |
| HPLC | High performance liquid chromatography |
| IB | Inclusion body |
| K222 | Kryptofix 222 |
| MeCN | Acetonitrile |
| mHTT | Mutant huntingtin |
| MRI | Magnetic Resonance Imaging |
| MSN | Medium spiny neuron |
| OTf | Trifluoromethanesulfonate, triflate |
| PET | Positron Emission Tomography |
| PD | Parkinson’s disease |
| RCP | Radiochemical purity; defined as the absence of other radiochemical compounds/species |
| RCY | Radiochemical yield; defined as the amount of activity in the product expressed as the percentage (%) of starting activity used in the considered process, all RCYs presented in this review are decay corrected |
| RT | Room temperature |
| SUV | Standardised uptake value |
| WT | Wildtype |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.